Benralizumab for PDGFRA-Negative Hypereosinophilic Syndrome

• Published in: The New England journal of medicine Vol. 380; no. 14; pp. 1336 - 1346
• Main Authors: Kuang, Fei Li, Legrand, Fanny, Makiya, Michelle, Ware, JeanAnne, Wetzler, Lauren, Brown, Thomas, Magee, Tamika, Piligian, Brent, Yoon, Pryscilla, Ellis, Jamie H, Sun, Xiaoping, Panch, Sandhya R, Powers, Astin, Alao, Hawwa, Kumar, Sheila, Quezado, Martha, Yan, Li, Lee, Nancy, Kolbeck, Roland, Newbold, Paul, Goldman, Mitchell, Fay, Michael P, Khoury, Paneez, Maric, Irina, Klion, Amy D
• Format: Journal Article
• Language: English
• Published: United States Massachusetts Medical Society 04.04.2019
• Subjects: Allergies; Asthma; Bone marrow; Clinical trials; Cytokines; Double-blind studies; Drug dosages; Eosinophilia; FDA approval; Headache; Immunosuppressive agents; Infectious diseases; Interleukin 5; L-Lactate dehydrogenase; Lactic acid; Leukocytes (eosinophilic); Monoclonal antibodies; Patients; R&D; Research & development

Benralizumab, an interleukin-5 receptor blocker, significantly reduced absolute eosinophil counts and relieved symptoms in a small group of patients with hypereosinophilic syndrome. Adverse events were similar in the benralizumab group and the placebo group.